Next Phase Newsletter

A firm with offices in China is managing two funds in RMB with a total of over 300M RMB, and is planning to raise a USD fund in the near future.

The firm is currently focusing on early-stage (from angel to series A) investments, each investment ranging from 5MM RMB (~0.7MM) to 20MM RMB (~3MM).

With the support of a synergistic incubator business and its accelerating program, as well as a dynamic innovation ecosystem built upon these business arms, the firm has a broad reach of disruptive technologies and is progressively investing in the field of life science to support the business strategy and organic growth of their parent company.

The firm is mainly looking at fields of next generation of molecule diagnostics, microfluidics, synthetic biology, omics technology, bioinformatics, genetic testing, gene therapy and immunotherapy, microbiome, etc. The firm is open to investing in the field of life science and precision medicine, focusing on the frontier research and technologies in DNA, RNA, protein, cell, tissue and other integrative omics. Therapeutics, especially gene therapy, oncology therapy, and eye disease therapy; diagnostics sector, especially in gene detection, molecular diagnostics, CNS and IVD; also some medical devices. However, the firm has less interest in technologies that are already in the field of very fierce competition, with big players already in.

The firm prefers companies with a China angle, especially companies who are willing to register an entity in China. They mostly are interested in companies with novel and original technologies and a clear direction of clinical applications.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A  corporate venture capital arm of a global pharmaceutical with headquarters in Western Europe can invest up to $5m to a round. They will participate in rounds for digital health companies at all stages, as early as seed and through later venture rounds. They are open to working with companies globally.

Within digital health, the firm is seeking companies that are in the prevention and adherence space as well as digital medical devices and big data analytics platforms that address chronic diseases (Diabetes, Obesity and Cardiovascular), respiratory diseases, oncology, consumer and mental health. Past investments in the space include a wearable nicotine delivery device with integrated software and data analytics component to aid in smoking cessation.

The firm prefers to work with management teams with a track record in the space and a strong business plan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Western Europe owns several funds and currently focuses on investments in Europe based diagnostics companies. The firm invests in Europe and North America, and typically allocates about €5 million equity to each portfolio company, generally over several tranches.

The firm invests in therapeutics and diagnostics to treat rare diseases.  The firm is agnostic regarding technologies and indication areas, and typically invests early but is open to companies with assets ranging from preclinical development through Phase II.

The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm that represents a high net worth family office has offices in Western Europe. The firm makes equity investments in life science companies, typically at the Series B stage or later; the firm allocates a total of EUR 3-10 million over the life of an investment. The firm invests in Europe and the US.

In the life science sector, the firm invests in medical applications (therapeutics, diagnostics, and medical devices), life science services and tools, and agtech / food tech. For therapeutics companies, the firm only invests in companies with assets that have obtained data from in-human clinical trials (at minimum, human safety data is required). For medtech or diagnostic companies, the product must be no more than 1 year from commercialization. The firm invests broadly in the life science field, but has a specific interest in technologies at the intersection between the healthcare and food industries, including nutraceuticals and the microbiome.

The firm is a hands-on investor that prefers to take a board seat and work closely with management, and therefore prefers to invest in companies located close to their offices. The firm prefers to invest as part of a strong syndicate that includes experienced investors with whom the firm has pre-existing connections.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family investment group based in the USA is looking to invest in technologies related to ophthalmology and oncology that are in the pre-clinical to Ph I stages. The firm will invest in seed and series A rounds up to $10M. The firm is willing to invest globally, with a special interest in companies based in North America, Europe and China.

The firm is interested in therapeutics, medical device and diagnostics companies with technologies in the ophthalmology and oncology spaces. The firm may consider digital health companies as well. For ophthalmology-related companies, Halcyon is most interested in small molecules or combination devices. For oncology-related companies, the firm prefers I/O technologies or diagnostics.

The firm prefers to take a board seat after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital arm of a large Asian financial conglomerate mainly invests in the IT, communications, cultural/creative, alternative energies, biotechnology, and medical/healthcare sectors. The firm seeks to invest in commercial stage or expansion phase companies that are 3-5 years from IPO. Typical equity allocations range from US$1-3 million and can be up to US$5 million. The firm is now focused on China and South East Asia, with interest in opportunities from North America and Europe to a lesser extent.

Within healthcare, the firm is interested in all sectors of medical technology, including consumer and non-consumer products. The firm is agnostic to indications. The firm is less interested in therapeutics, but it would consider drug reformulation. The firm looks for products that are ready for commercialization or at the commercial stage and seeking growth/expansion capital.

The firm looks for a strong and experienced management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment group based out of the USA is a wholly owned subsidiary of a large healthcare system. The firm engages in strategic investments across a wide variety of sectors to benefit the health system. The firm invests at a set pace with ~2 surgery centers being invested in per year and are currently looking to diversify their portfolio. The firm tends to invest in seed and pre-revenue rounds as their allocation size is on the smaller side, but is interested in revenue generating opportunities with smaller rounds.

The firm is particularly interested in technologies that can help them increase the quality of care, decrease the cost of care, and increase the access of services to populations which have been historically denied. Beyond that though, the firm is rather opportunistic within the healthcare IT, medical devices, healthcare services, and care delivery spaces and currently has no specific focus.

The firm requires that companies have some sort of relationship with the firm or have the endorsement of the senior management of the health system.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.